Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MDLast reviewed:
GIST and Neuroendocrine Tumors
Pathology-driven rare tumors
GIST and NET are not “stomach cancer packages.”
Gastrointestinal stromal tumors (GIST) and neuroendocrine tumors (NET) need pathology, mutation or grade data, and organ-specific planning. They are not managed with a generic gastric-adenocarcinoma checklist. Selected small, low-risk gastric GIST may be surveilled; PDGFRA D842V changes tyrosine-kinase expectations including imatinib resistance. NET versus neuroendocrine carcinoma (NEC) separation is critical — biology and urgency differ. Surgery, TKIs, somatostatin analogs, and peptide-receptor therapies enter only after the report answers the right questions.
- Hero figure: GIST and neuroendocrine tumor overview.
- Related figures support diagnosis, staging language, and treatment pathway concepts.
Educational figures
Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.
GIST NET Diagnosis Treatment
What to know
- Key note inside
GIST surveillance limits
Surveillance is limited to selected small, especially gastric, non–high-risk lesions. Size, site, and mitotic features decide.
- Key note inside
Mutation-aware TKI talk
D842V is not a standard imatinib success story.KIT and PDGFRA context matter. Assuming imatinib works for PDGFRA D842V is a planning error.
NET localization and grade
Grade, Ki-67, organ, size, and behavior individualize care for localized G1–G2 disease.
- Key note inside
NET versus NEC
If the report does not clearly separate NET from NEC, therapy should not be locked. NEC behaves differently and often more urgently.
Surgery still has a role
Resectable primary disease and selected metastases are discussed with mutation/grade context — not postponed forever for “rare tumor mystique.”
What happens next
GIST — explained for shared decision-making
- 1
Gastrointestinal Stromal Tumor (GIST)
GIST — explained for shared decision-making
Read this chapter - 2
Neuroendocrine Tumors (NET)
NET — explained for shared decision-making
Read this chapter - 3
GIST & NET Diagnosis
How clinicians confirm the problem and stage the next steps
Read this chapter - 4
GIST & NET Treatment
How treatment options are matched to risk, stage, and goals
Read this chapter
Scientific evidence atlas
Plain-language summaries of the key clinical trials behind current treatment decisions.
GIST Landmark Atlas
Surgery, mutation testing, and tyrosine kinase inhibitors in GIST: imatinib in advanced disease (B2222), adjuvant imatinib after surgery (Z9001, SSGXVIII/AIO), later-line treatment (GRID, INVICTUS), and PDGFRA D842V-mutant GIST (NAVIGATOR).
Open the atlas →NET (Neuroendocrine Tumor) Landmark Atlas
Not every NET is the same. Covers PROMID, CLARINET, NETTER-1/2, RADIANT-3/4, sunitinib in pNET, CABINET, E2211, SEQTOR, and COMPETE. NET is not NEC; dotatate is not edotreotide.
Open the atlas →
Appointment / info
Pathology with IHC and mutation details is the most useful document you can bring.
This page is for education. It is not medical advice and does not replace a visit with your physician.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.